hIL-12 gene therapy (Mount Sinai)

N/A

Report date: 2023/10/26 17:02:21

Base Information

Drug NamehIL-12 gene therapy (Mount Sinai)
Drug Alias NameAd.hIL-12
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionInterleukin-12 stimulants
TargetsInterleukin-12
Therapy Area/IndicationsNeoplasm MetastasisProstatic NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIcahn School Of Medicine At Mount Sinai
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIcahn School Of Medicine At Mount SinaiNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisProstatic NeoplasmsColorectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A